All In Biotech

Drug Trial Radar · NCT03684694

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)

Last checked: Nov 20, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

136

Actual

Start

Dec 1, 2018

Primary completion

Nov 8, 2022

Study completion Nov 8, 2022

Sponsor

Lead sponsor
ADC Therapeutics S.A.Industry
Sponsor type
Industry
First posted
Sep 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.

Conditions

  • Diffuse Large B-Cell Lymphoma
  • Mantle Cell Lymphoma

Interventions

  • Loncastuximab TesirineDrug

    Intravenous (IV) infusion.

  • IbrutinibDrug

    Oral capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)
  2. Phase 1: Number of Participants With Serious TEAEsTime frame: Day 1 until 30 days after last dose; max duration of treatment was 686 days for Phase 1 (up to approximately 716 days total)
  3. Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: 21 days
  4. Phase 1: Number of Participants With Dose InterruptionsTime frame: Up to a maximum of 686 days
  5. Phase 1: Number of Participants With Dose ReductionsTime frame: Up to a maximum of 686 days
  6. Phase 2: Complete Response Rate (CRR)Time frame: Up to approximately 38 months

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Irvine Health Chao Family Comprehensive Cancer Center

    Orange, California

  • Redlands Community Hospital

    Redlands, California

  • University of Miami

    Miami, Florida

  • Miami Cancer Institute

    Miami, Florida

  • The Blood and Marrow Transplant Group of Georgia

    Atlanta, Georgia

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Saint Vincent Healthcare

    Billings, Montana

  • Case Western Reserve University

    Cleveland, Ohio

  • GasthuisZusters Antwerpen Sint-Augustinus

    Wilrijk, Belgium

  • CHU UCL Namur (Site Godinne)

    Yvoir, Belgium

  • Centre Hospitalier Universitaire de Rennes Hôpital Pontchailou

    Bretagne, France

  • Hôpital Hôtel-Dieu

    Loiré, France

  • Hôpital Saint-Eloi

    Montpellier, France

  • Hôpital Saint-Louis

    Paris, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Centre Hospitalier Universitaire De Poitier - Hopital De La Miletrie - Hopital Jean Bernard

    Poitiers, France

  • Azienda Ospedaliera Pap Giovanni XXIII

    Bergamo, Italy

  • Policlinico Sant'Orsola Malpighi

    Bologna, Italy

  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

    Brescia, Italy

  • Istituto Scientifico Rmagnolo per lo Studio e la Cura dei Tumori

    Meldola FC, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Azienda Unita Sanitaria Locale de Ravenna

    Ravenna, Italy

  • IRCCS istituto Clinico Humanitas U.O. di Oncologia ed Ematologia

    Via Manzoni, Rozzano, Italy

  • Hospital Universitario Vall d'Hebrón

    Barcelona, Spain

  • Hospital Duran I Reynals

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Abertawe Bro Morgannwg University Health Board

    Swansea, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.